ThrombosisCVCCPNCT01661218
Complications and Risk Factors Related With Central Venous Catheters in Cancer Patients
An observational study of Thrombosis and Infections, run by Beijing Huanxing Cancer Hospital at 1 site in China.
Trial summary
The investigators aim to determine the complications and risk factors related with peripherally inserted central catheters (PICCs) and central venous catheters (CVCs) in cancer patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Thrombosis, Infections
- How many people
- 3,500 participants
- Where
- 1 siteChina
- Study dates
- Aug 2012to Aug 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All adult cancer patients with CVC and PICC placed at BeijingHCH and with written consent for this study
Who may be able to join
- all adult cancer patients with central venous catheters (CVCs) or peripherally inserted central catheters (PICCs) placed at BeijingHCH.
Who cannot join
- without written informed consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Complications and Risk Factors Related With Central Venous Catheters in Cancer Patients(CVCCP)
The investigators aim to determine the complications and risk factors related with peripherally inserted central catheters (PICCs) and central venous catheters (CVCs) in cancer patients.
Read the detailed description
The purpose of this study is to determine the complications and risk factors related with peripherally inserted central catheters (PICCs) and central venous catheters (CVCs) in cancer patients.
- Conditions
- Thrombosis, Infections
- Keywords
- catheters, Central Venous, complications, cancer
- Medical subject headings
- Thrombosis, Infections, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| complications | catheter-related venous thrombosis catheter-related infections |
What is being measured
The primary outcome is the main question the study is designed to answer.
Catheter-related venous thrombosis and catheter-related infections
Catheter-related venous thrombosis and catheter-related infections
Measured: 30 days after PICC and CVC line withdrawn
Secondary outcomes (1)
Catheter tip position
Catheter tip position
Measured: participants will be followed before PICC and CVC line withdrawn
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2012 (estimated)
- Study startAug 2012
- Primary completionAug 2019
- Study completionAug 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ThrombosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,500 participants (actual)
Sponsor and investigators
- Lead sponsor
- Beijing Huanxing Cancer Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jian DING, MD, Study chair, Beijing Huanxing Cancer Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01661218
- Sponsor's protocol ID
- HCH20120530
- Other IDs
- HCH20120530-008
- Acronym
- CVCCP
- Status last verified
- Aug 2012
- First submitted
- 2 Aug 2012
- Last updated
- 3 Sep 2020
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Complications and Risk Factors Related With Central Venous Catheters in Cancer Patients(CVCCP)
- ClinicalTrials.gov ID
- NCT01661218
- Acronym / sponsor ID
- CVCCP / HCH20120530
- Conditions
- Thrombosis, Infections
- Keywords
- catheters, Central Venous, complications, cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,500 participants (actual)
- Lead sponsor
- Beijing Huanxing Cancer HospitalUniversity, hospital or other
- Study start
- Aug 2012
- Primary completion
- Aug 2019 (actual)
- Study completion
- Aug 2019 (actual)
- First posted
- 9 Aug 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators aim to determine the complications and risk factors related with peripherally inserted central catheters (PICCs) and central venous catheters (CVCs) in cancer patients.
Detailed description
The purpose of this study is to determine the complications and risk factors related with peripherally inserted central catheters (PICCs) and central venous catheters (CVCs) in cancer patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| complications | – | –catheter-related venous thrombosis catheter-related infections |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All adult cancer patients with CVC and PICC placed at BeijingHCH and with written consent for this study
Key inclusion criteria (1 listed)
- all adult cancer patients with central venous catheters (CVCs) or peripherally inserted central catheters (PICCs) placed at BeijingHCH.
Key exclusion criteria (1 listed)
- without written informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Catheter-related venous thrombosis and catheter-related infections
Time frame: 30 days after PICC and CVC line withdrawn
Catheter-related venous thrombosis and catheter-related infections
1 secondary outcome
Catheter tip position
Time frame: participants will be followed before PICC and CVC line withdrawn
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2020.
Related trials for Thrombosis
Not yet recruitingPhase 3
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
RecruitingObservational study
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
Pulmonary Embolism
RecruitingPhase 2
SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
HCC
Not yet recruiting
Pilot Study Evaluating Catheter Directed Thrombolysis Device in Acute Intermediate Risk Pulmonary Embolism
Pulmonary Embolism (PE), Pulmonary Embolism With Right Ventricle Enlargement
Active, not recruitingObservational study
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jian DING, MD study chair
Beijing Huanxing Cancer Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Thrombosis and Infections, run by Beijing Huanxing Cancer Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Catheter-related venous thrombosis and catheter-related infections (time frame: 30 days after PICC and CVC line withdrawn). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2020.